ALVO:NSD-Alvotech (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 14.15

Change

+0.50 (+3.66)%

Market Cap

USD 3.82B

Volume

0.25M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

-4.17 (-2.91%)

USD 13.68B
VTRS Viatris Inc

+0.09 (+0.77%)

USD 13.36B
ITCI Intracellular Th

-4.21 (-5.91%)

USD 7.72B
LNTH Lantheus Holdings Inc

-1.50 (-1.97%)

USD 4.49B
ALKS Alkermes Plc

-0.49 (-1.99%)

USD 4.08B
AVDL Avadel Pharmaceuticals PLC

-1.93 (-10.62%)

USD 3.39B
HCM HUTCHMED DRC

+0.02 (+0.10%)

USD 3.23B
INDV Indivior PLC Ordinary Shares

+0.08 (+0.45%)

USD 2.93B
EVO Evotec SE ADR

+0.05 (+0.97%)

USD 2.51B
AMPH Amphastar P

-0.56 (-1.31%)

USD 2.09B

ETFs Containing ALVO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.26% 78% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.26% 78% C+ 85% B
Trailing 12 Months  
Capital Gain 44.39% 87% B+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.39% 87% B+ 86% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.91% 68% D+ 69% C-
Dividend Return 9.91% 68% D+ 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 16.74% 96% N/A 80% B-
Risk Adjusted Return 59.19% 94% A 86% B+
Market Capitalization 3.82B 94% A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.